Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

Clinical Microbiology and Infection

Volumn 21, Issue 3, 2015, Pages 217-221

  Jones, M ^a   Jefferson, T ^b   Doshi, P ^c   Del Mar, C ^d   Heneghan, C ^e   Onakpoya, I ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b The Cochrane Collaboration   (Italy)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d BOND UNIVERSITY   (Australia)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical study reports; Influenza; Neuraminidase inhibitors; Reporting bias; Systematic review

Indexed keywords

OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ADULT; ANTIVIRAL THERAPY; CHILD; CLINICAL STUDY; COCHRANE LIBRARY; DRUG EFFICACY; EUROPEAN MEDICINES AGENCY; HUMAN; INFECTION PREVENTION; INFLUENZA; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; META ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CHILD; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; TREATMENT OUTCOME;

EID: 84933529300     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.10.011     Document Type: Review

References (12)

1. Jefferson T., Demicheli V., Di Pietrantonj C., Jones M., Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006, (3):CD001265.
2. Kaiser L., Wat C., Mills T., Mahoney P., Ward P., Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003, 163:1667-1672.
3. Doshi P. Neuraminidase inhibitors-the story behind the Cochrane review. BMJ 2009, 339:b5164.
4. Jefferson T., Jones M., Doshi P., Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009, 339:b5106.
5. Doshi P., Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 2013, 3(2):e002496. http://bmjopen.bmj.com/content/3/2/e002496.full.
6. Jefferson T., Jones M.A., Doshi P., Del Mar C.B., Heneghan C.J., Hama R., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012, (1):CD008965.
7. Cohen D. Complications: tracking down the data on oseltamivir. BMJ 2009, 339:b5387.
8. Jefferson T., Jones M.A., Doshi P., Del Mar C.B., Hama R., Thompson M.J., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014, (4):CD008965.
9. Herxheimer A., Clarke M., Edwards R., Jefferson T., Loke Y. Time for case-control studies of NSAIDs and oseltamivir. BMJ 2009, 339:b3048.
10. Dunn A., Arachi D., Hudgins J., Tsafnat G., Coiera E., Bourgeois F. Financial Conflicts of Interest and Conclusions About Neuraminidase Inhibitors for Influenza. Ann Intern Med 2014, 161:513-518.
11. Lexchin J., Bero L.A., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003, 326:1167-1170.
12. Lundh A., Sismondo S., Lexchin J., Busuioc O.A., Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012, 12:MR000033. 10.1002/14651858.MR000033.pub2.